Skip to main content
Clinical Trials/NCT04220450
NCT04220450
Unknown
Not Applicable

T1-mapping by Cardiovascular Magnetic Resonance Imaging to Assess Non-Alcoholic Fatty Liver Disease

Dr. Andreas Kammerlander1 site in 1 country800 target enrollmentStarted: June 1, 2020Last updated:

Overview

Phase
Not Applicable
Sponsor
Dr. Andreas Kammerlander
Enrollment
800
Locations
1
Primary Endpoint
Correlation NAFLD and liver T1mapping

Overview

Brief Summary

On clinically indicated Cardiovascular Magnetic Resonance studies, native T1-times and extracellular volume of the liver will be assessed and findings correlated with established risk calculators for non-alcoholic fatty liver disease.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Cross Sectional

Eligibility Criteria

Ages
18 Months to — (Child, Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Referred for Cardiovascular Magnetic Resonance Imaging

Exclusion Criteria

  • Non-compatible Devices

Outcomes

Primary Outcomes

Correlation NAFLD and liver T1mapping

Time Frame: cross-sectional within one year

Correlation NAFLD risk score and liver T1-mapping (native and ECV9

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor
Dr. Andreas Kammerlander
Sponsor Class
Other
Responsible Party
Sponsor Investigator
Principal Investigator

Dr. Andreas Kammerlander

Principal Investigator

Medical University of Vienna

Study Sites (1)

Loading locations...

Similar Trials